ReviewAbdominal radiology (New York)2026
Image-guided percutaneous ablation techniques for the treatment of renal cell carcinoma: a primer for radiologists.
Review in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Percutaneous renal tumor ablation (RTA) has become an established treatment option for selected patients with small renal masses, particularly cT1a tumors in patients with relevant comorbidity, hereditary renal tumor syndromes, impaired renal function, or a solitary kidney. In this review, we summarize current indications for RTA, the main ablation technologies, image-guidance strategies, preprocedural planning, adjunctive techniques, intraprocedural considerations, complications, and post-ablation follow-up. We also review current evidence comparing RTA with partial nephrectomy, with particular attention to oncologic outcomes, renal function preservation, and morbidity. Although guideline recommendations remain relatively conservative, accumulating evidence supports percutaneous ablation as an important nephron-sparing treatment option in appropriately selected patients. This review aims to provide radiologists with a practical overview of contemporary renal tumor ablation and its role in the multidisciplinary management of renal cell carcinoma.
Indexed as
Identifiers
42240648What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.